3-Bromo-4-prop-2-enylpyridine | 200629-14-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-Bromo-4-prop-2-enylpyridine
• CAS: 200629-14-7
• 化学式: C₈H₈BrN
• 分子量: 198.062
• InChiKey: LSHPWDSFXGFIRW-UHFFFAOYSA-N

物化性质

• 沸点：
  235.5±25.0 °C(Predicted)
• 密度：
  1.382±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-Bromo-4-prop-2-enylpyridine 在 sodium periodate 、 四氧化锇 、 palladium (II) bis(triphenylphosphine) bis(trifluoroacetate) 、 N,N-二异丙基乙胺 、 zinc(II) iodide 、 potassium hexacyanoferrate(III) 作用下， 以 xylene 为溶剂， 生成 (6S,6aS,10aR)-13-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-yl)-6,6a,7,8-tetrahydro-5H-6,10a-(epiminoethano)benzo[h]isoquinoline
  参考文献：
  名称：

  Pyridinomorphinans: Asymmetric synthesis of either enantiomer and opioid receptor binding selectivity

  摘要：

  Either enantiomer of a new class of morphinans in which the aryl ring is replaced by a pyridine ring can be prepared by sequential iminium ion-allylsilane cyclization and intramolecular Heck insertion. Pyridinomorphinan 5 exhibits high affinity for the mu opioid receptor. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0040-4039(97)10274-x
• 作为产物：
  描述：

  3-溴吡啶 、 丙烯酰碘 在 lithium diisopropyl amide 作用下， 以40%的产率得到3-Bromo-4-prop-2-enylpyridine
  参考文献：
  名称：

  Pyridinomorphinans: Asymmetric synthesis of either enantiomer and opioid receptor binding selectivity

  摘要：

  Either enantiomer of a new class of morphinans in which the aryl ring is replaced by a pyridine ring can be prepared by sequential iminium ion-allylsilane cyclization and intramolecular Heck insertion. Pyridinomorphinan 5 exhibits high affinity for the mu opioid receptor. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0040-4039(97)10274-x

文献信息

• [EN] AZAINDAZOLE COMPOUNDS<br/>[FR] COMPOSÉS AZAINDAZOLE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2012009510A1

  公开（公告）日：2012-01-19

  Disclosed are azaindazole compounds of Formula (I), or pharmaceutically acceptable salts thereof, wherein W is CR4 or N; and R1, R2, R3, and R4 are defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP17 associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.

  本文披露了式（I）的吡唑嗪化合物或其药用盐，其中W是CR4或N；R1、R2、R3和R4在此有定义。还披露了使用这种化合物治疗至少一种CYP17相关疾病的方法，例如癌症，以及包含这种化合物的药物组合物。
• AZAINDAZOLE COMPOUNDS
  申请人：Velaparthi Upender

  公开号：US20130184254A1

  公开（公告）日：2013-07-18

  Disclosed are azaindazole compounds of Formula (I), or pharmaceutically acceptable salts thereof, wherein W is CR 4 or N; and R 1 , R 2 , R 3 , and R 4 are defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP17 associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.

  本发明涉及式(I)的吡唑嗪化合物，或其药学上可接受的盐，其中W为CR4或N；R1、R2、R3和R4在此定义。本发明还涉及使用这种化合物治疗至少一种CYP17相关疾病的方法，例如癌症，以及包含这种化合物的制药组合物。
• [EN] SUBSTITUTED 3-PYRIDYL THIOPHENES AS C17,20 LYASE INHIBITORS<br/>[FR] 3-PYRIDYL THIOPHENES SUBSTITUES EN TANT QU'INHIBITEURS DE LA LYASE C17,20
  申请人：BAYER AG

  公开号：WO2003027105A1

  公开（公告）日：2003-04-03

  The invention provides novel substituted 3-pyridyl thiophenes and pharmaceutical compositions thereof. The invention also provides methods of use of substituted 3-pyridyl thiophenes, and pharmaceutical compositions thereof, as inhibitors of lyases, e.g., the 17α-hydroxylase-C17,20 enzyme. The invention further provides methods for the treatment of cancer in a subject, comprising administering a substituted 3-pyridyl thiophenes, or a pharmaceutical composition comprising a substituted 3-pyridyl thiophenes to a subject. The cancer can be, e.g., prostate cancer or breast cancer.

  本发明提供了一种新型的取代3-吡啶基噻吩衍生物及其医药组合物。本发明还提供了取代3-吡啶基噻吩衍生物及其医药组合物作为裂合酶抑制剂的用途，例如作为17α-羟化酶-C17,20酶的抑制剂。本发明进一步提供了一种针对受试者治疗癌症的方法，包括向受试者施用取代3-吡啶基噻吩衍生物或含有取代3-吡啶基噻吩衍生物的医药组合物。所述癌症可以是例如前列腺癌或乳腺癌。
• US8673922B2
  申请人：——

  公开号：US8673922B2

  公开（公告）日：2014-03-18
• [EN] SUBSTITUTED 3-PYRIDYL PYRROLES AND 3-PYRIDYL PYRAZOLES AS C17,20 LYASE INHIBITORS<br/>[FR] 3-PYRIDYL PYRROLES ET 3-PYRIDYL PYRAZOLES SUBSTITUES EN TANT QU'INHIBITEURS DE LA LYASE C17,20
  申请人：BAYER AG

  公开号：WO2003027101A1

  公开（公告）日：2003-04-03

  The invention provides novel substituted 3-pyridyl pyrroles and 3-pyridyl pyrazoles and pharmaceutical compositions thereof. The invention also provides methods of use of substituted 3-pyridyl pyrroles and 3-pyridyl pyrazoles and pharmaceutical compositions thereof as inhibitors of lyases, e.g., the 17α-hydroxylase-C17,20 enzyme. The invention further provides methods for the treatment of cancer in a subject, comprising administering a substituted 3-pyridyl pyrroles and 3-pyridyl pyrazoles or a pharmaceutical composition comprising a substituted 3-pyridyl pyrroles and 3-pyridyl pyrazoles to a subject. The cancer can be, e.g., prostate cancer or breast cancer.